Penumbra wins FDA clearance for DVT treatment technology

Tue, 20 Oct 2026 09:03:54 -0400

Penumbra, Inc. (NYSE: PEN) said the U.S. Food and Drug Administration has cleared its Lightning computer assisted vacuum thrombectomy (CAVT) technology for the treatment of deep vein thrombosis (DVT), according to a company statement.

The clearance is supported by results from the BOLT-DVT Investigational Device Exemption trial, a prospective, multicenter study evaluating CAVT as a first-line treatment for acute iliofemoral DVT. In the trial, 98% of patients experienced complete or near-complete thrombus removal, with a median device time of 18 minutes and a 48-hour major adverse event rate of 3.1%.

Additional trial findings included a 30-day re-thrombosis rate of 3.9%, 30-day patency

Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)

Tue, 20 Oct 2026 09:00:00 -0400

BOLT-DVT, a recent prospective, multicenter Investigational Device Exemption (IDE) trial, demonstrated first-line use of computer assisted vacuum thrombectomy (CAVT) for DVT is safe and effective

ALAMEDA, Calif., Oct. 20, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced that the U.S. Food and Drug Administration (

Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)

Tue, 20 Oct 2026 09:00:00 -0400

BOLT-DVT, a recent prospective, multicenter Investigational Device Exemption (IDE) trial, demonstrated first-line use of computer assisted vacuum thrombectomy (CAVT) for DVT is safe and effective

ALAMEDA, Calif., Oct. 20, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced that the U.S. Food and Drug Administration (

Form 4 Penumbra Inc For: Oct 15 Filed by: Narayan Shruthi

Fri, 16 Oct 2026 19:36:00 -0400

si-local-file:///var/storage/secattach/20261016/27198979.html

New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism

Tue, 06 Oct 2026 09:00:00 -0400

Wearable-derived data provide new insights into how clinical outcomes for patients treated with CAVT and anticoagulation, and anticoagulation alone translate to patients' everyday recovery

ALAMEDA, Calif., Oct. 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) announced results from a subset analysis of the landmark STORM-PE randomized controlled trial (RCT), the first trial

New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism

Tue, 06 Oct 2026 09:00:00 -0400

Wearable-derived data provide new insights into how clinical outcomes for patients treated with CAVT and anticoagulation, and anticoagulation alone translate to patients' everyday recovery

ALAMEDA, Calif., Oct. 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) announced results from a subset analysis of the landmark STORM-PE randomized controlled trial (RCT), the first trial

Form 4 Penumbra Inc For: Sep 15 Filed by: Narayan Shruthi

Thu, 17 Sep 2026 19:32:00 -0400

si-local-file:///var/storage/secattach/20260917/27077152.html

Form 4 Penumbra Inc For: Aug 17 Filed by: Narayan Shruthi

Wed, 19 Aug 2026 19:23:00 -0400

si-local-file:///var/storage/secattach/20260819/26951543.html

Form 4 Penumbra Inc For: Aug 17 Filed by: Narayan Shruthi

Wed, 19 Aug 2026 19:23:00 -0400

si-local-file:///var/storage/secattach/20260819/26951543.html

Form SCHEDULE 13G Penumbra Inc Filed by: BARCLAYS PLC

Thu, 13 Aug 2026 18:48:00 -0400

si-local-file:///var/storage/secattach/20260813/26923086.html

Form SCHEDULE 13G Penumbra Inc Filed by: BARCLAYS PLC

Thu, 13 Aug 2026 18:48:00 -0400

si-local-file:///var/storage/secattach/20260813/26923086.html

Penumbra, Inc. (PEN) Misses Q2 EPS by 28c

Thu, 30 Jul 2026 17:00:27 -0400

Penumbra, Inc. (NYSE: PEN) reported Q2 EPS of $0.88, $0.28 worse than the analyst estimate of $1.16. Revenue for the quarter came in at $390.04 million versus the consensus estimate of $389.61 million.

For earnings history and earnings-related data on Penumbra, Inc. (PEN) click here.

Form 10-Q Penumbra Inc For: Jun 30

Thu, 30 Jul 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260730/26844481.html

Form 10-Q Penumbra Inc For: Jun 30

Thu, 30 Jul 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260730/26844481.html

Form 8-K Penumbra Inc For: Jul 30

Thu, 30 Jul 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260730/26843770.html

Form 8-K Penumbra Inc For: Jul 30

Thu, 30 Jul 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260730/26843770.html

Penumbra, Inc. Reports Second Quarter 2026 Financial Results